Mithra Strengthens Position in the Belgian Contraception Market

  • Mithra builds on leading position in Belgian contraceptive market
  • Mithra achieves significant increase in 2016 sales
  • Market trend validates Mithra’s Estetrol-based programs

Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.

Mithra Strengthens Position in the Belgian Contraception Market

  • Mithra builds on leading position in Belgian contraceptive market
  • Mithra achieves significant increase in 2016 sales
  • Market trend validates Mithra’s Estetrol-based programs

Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.

Mithra Strengthens Position in the Belgian Contraception Market

  • Mithra builds on leading position in Belgian contraceptive market
  • Mithra achieves significant increase in 2016 sales
  • Market trend validates Mithra’s Estetrol-based programs

Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.

Mithra Plans to Submit Myring for US and EU Approval in Q2 2017

Planned submissions follow successful trials demonstrating bioequivalence to NuvaRing®

Liège, Belgium, 24 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it intends to submit its combined hormonal contraceptive vaginal ring, Myring, for marketing approval in both Europe and the United States in Q2 2017.

Mithra Plans to Submit Myring for US and EU Approval in Q2 2017

Planned submissions follow successful trials demonstrating bioequivalence to NuvaRing®

Liège, Belgium, 24 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it intends to submit its combined hormonal contraceptive vaginal ring, Myring, for marketing approval in both Europe and the United States in Q2 2017.

Mithra Plans to Submit Myring for US and EU Approval in Q2 2017

Planned submissions follow successful trials demonstrating bioequivalence to NuvaRing®

Liège, Belgium, 24 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it intends to submit its combined hormonal contraceptive vaginal ring, Myring, for marketing approval in both Europe and the United States in Q2 2017.

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive

Liège, Belgium, 18 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive.

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive

Liège, Belgium, 18 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive.

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive

Liège, Belgium, 18 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive.

Mithra’s North American Advisory Board for Donesta® Will Meet in Miami, Florida 20th- 21st January 2017

  • Mithra has set up scientific advisory boards composed of international experts to support the development of Donesta®, its product candidate for menopause based on Estetrol (E4).
  • The North American scientific advisory board, set up by Mithra, is aiming at gathering additional development guidance from international experts in the menopause field.